IL23A and experimental autoimmune encephalomyelitis: In experimental autoimmune encephalomyelitis (EAE; a mouse model for human multiple sclerosis), however, anti-IL-23p19 effectively ameliorated EAE when treatment was started at disease onset, peak of disease, or even during the first remission (Kikly et al., unpublished data).